Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE-/- mice and angiogenesis

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 2946-2960

  Escudero, P ^a,b   Navarro, A ^a   Ferrando, C ^a,c   Furio, E ^a   Gonzalez Navarro, H ^a   Juez, M ^c   Sanz, M J ^a,b   Piqueras, L ^a  

^a Instituto Universitario IVI INCLIVA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BEXAROTENE; CXCL1 CHEMOKINE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; P70S6 KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RANTES; RETINOID X RECEPTOR ALPHA; ROSUVASTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; TETRALIN DERIVATIVE;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CAPILLARY DENSITY; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MIGRATION INHIBITION; MONOCYTE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; ROSUVASTATIN CALCIUM; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES;

EID: 84930226772     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13098     Document Type: Article

References (63)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
5. Angelo LS, Kurzrock R, (2007). Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13: 2825-2830.
6. Babelova A, Sedding DG, Brandes RP, (2013). Anti-atherosclerotic mechanisms of statin therapy. Curr Opin Pharmacol 13: 260-264.
7. Balakumar P, Mahadevan N, (2012). Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol 165: 373-379.
8. Bechara C, Chai H, Lin PH, Yao Q, Chen C, (2007). Growth related oncogene-alpha (GRO-alpha): roles in atherosclerosis, angiogenesis and other inflammatory conditions. Med Sci Monit 13: RA87-RA90.
9. Cao J, Gong L, Guo DC, Mietzsch U, Kuang SQ, Kwartler CS, et al. (2010). Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. Hum Mol Genet 19: 1908-1920.
10. Choke E, Thompson MM, Dawson J, Wilson WR, Sayed S, Loftus IM, et al. (2006). Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol 26: 2077-2082.
11. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. (2012). ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335: 1503-1506.
12. Daugherty A, Rateri DL, Cassis LA, (2006). Role of the renin-angiotensin system in the development of abdominal aortic aneurysms in animals and humans. Ann N Y Acad Sci 1085: 82-91.
13. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. (2013). Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 346: f880.
14. Girardi JM, Farias RE, Ferreira AP, Raposo NR, (2011). Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats. Clinics (Sao Paulo) 66: 1457-1462.
15. Golledge J, Muller J, Daugherty ANorman P, (2006). Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 26: 2605-2613.
16. Golomb BA, Evans MA, (2008). Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8: 373-418.
17. Hafizi S, Wang X, Chester AH, Yacoub MH, Proud CG, (2004). ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. Am J Physiol Heart Circ Physiol 287: H1232-H1238.
18. Izhak L, Wildbaum G, Jung S, Stein A, Shaked Y, Karin N, (2012). Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS ONE 7: e28305.
19. Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M, (2010). Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159: 1294-1303.
20. Karar J, Maity A, (2011). PI3K/AKT/mTOR Pathway in angiogenesis. Front Mol Neurosci 4 (Article 51): 1-8.
21. Karnoub AE, Weinberg RA, (2008). Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531.
22. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
23. Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR, (2012). Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab 302: E201-E208.
24. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, et al. (2006). The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 26: 2731-2737.
25. Lawrence DM, Singh RS, Franklin DP, Carey DJ, Elmore JR, (2004). Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg 40: 334-338.
26. Lee SJ, Yang EK, Kim SG, (2006). Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 70: 415-425.
27. Manning MW, Cassi LA, Huang J, Szilvassy SJ, Daugherty A, (2002). Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease. Vasc Med 7: 45-54.
28. Mantovani A, Allavena P, Sica A, Balkwill F, (2008). Cancer-related inflammation. Nature 454: 436-444.
29. Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerda-Nicolas M, Proudfoot AE, et al. (2006). Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 176: 5577-5586.
30. Mayer C, Gruber HJ, Landl EM, Pailer S, Scharnagl H, Truschnig-Wilders M, et al. (2007). Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther 45: 319-327.
31. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
32. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJSayers RD, (2007). The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 45: 574-580.
33. Mihos CG, Pineda AM, Santana O, (2014). Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res 88: 12-19.
34. Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, et al. (2004). Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110: 3581-3586.
35. Nishibe T, Dardik A, Kondo Y, Kudo F, Muto A, Nishi M, et al. (2010). Expression and localization of vascular endothelial growth factor in normal abdominal aorta and abdominal aortic aneurysm. Int Angiol 29: 260-265.
36. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB, (2002). 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143-150.
37. Patterson KA, Zhang X, Wrobleski SK, Hawley AE, Lawrence DA, Wakefield TW, et al. (2013). Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res 131: 268-276.
38. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
39. Peng SX, Rockafellow BA, Skedzielewski TM, Huebert ND, Hageman W, (2009). Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. J Pharm Sci 98: 1877-1884.
40. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, et al. (2007). Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27: 63-69.
41. Plutzky J, (2011). The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res 108: 1002-1016.
42. Richmond A, (2002). Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2: 664-674.
43. Sanz MJ, Albertos F, Otero E, Juez M, Morcillo EJ, Piqueras L, (2012). Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-gamma activation. J Immunol 189: 411-424.
44. Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, et al. (2013). U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 168: 192-200.
45. Sharvit E, Abramovitch S, Reif S, Bruck R, (2013). Amplified inhibition of stellate cell activation pathways by PPAR-gamma, RAR and RXR agonists. PLoS ONE 8: e76541.
46. Soran H, Durrington P, (2008). Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 9: 2145-2160.
47. Stuck BJ, Lenski M, Bohm M, Laufs U, (2008). Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 283: 32562-32569.
48. Suffee N, Hlawaty H, Meddahi-Pelle A, Maillard L, Louedec L, Haddad O, et al. (2012). RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 15: 727-744.
49. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L, (2004). Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 11 (Suppl. 2): S126-S143.
50. Tamarat R, Silvestre JS, Durie M, Levy BI, (2002). Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 82: 747-756.
51. Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, et al. (2003). Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 60: 810-819.
52. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, et al. (2006). Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188: 51-58.
53. Wang C, Tao W, Wang Y, Bikow J, Lu B, Keating A, et al. (2010). Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 58: 418-426.
54. Wang C, Qin L, Manes TD, Kirkiles-Smith NC, Tellides GPober JS, (2014). Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2. J Exp Med 211: 395-404.
55. Wang JA, Chen WA, Wang Y, Zhang S, Bi H, Hong B, et al. (2011). Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms. Atherosclerosis 217: 90-96.
56. Wang Z, Dai H, Xing M, Yu Z, Lin X, Wang S, et al. (2013). Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes. J Cardiovasc Pharmacol Ther 18: 327-333.
57. Willis LM, El-Remessy AB, Somanath PR, Deremer DL, Fagan SC, (2011). Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond) 120: 307-319.
58. Wojcik BM, Wrobleski SK, Hawley AE, Wakefield TW, Myers DD Jr, Diaz JA, (2011). Interleukin-6: a potential target for post-thrombotic syndrome. Ann Vasc Surg 25: 229-239.
59. Xiao H, Qin X, Ping D, Zuo K, (2013). Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity. PLoS ONE 8: e59233.
60. Xin X, Yang S, Kowalski J, Gerritsen ME, (1999). Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-9121.
61. Yen WC, Lamph WW, (2005). The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 4: 824-834.
62. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW, (2006). A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer 94: 654-660.
63. Zhang Y, Naggar JC, Welzig CM, Beasley D, Moulton KS, Park HJ, et al. (2009). Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 29: 1764-1771.